IP Library › Granted Patent US 8,008,092
Granted Patent B2
US 8,008,092 · App. 12/247,722 · Granted Aug 30, 2011

CCR3 inhibition for ocular angiogenesis and macular degeneration

Assignee: University of Kentucky Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,008,092
App. No.
12/247,722
Granted
Aug 30, 2011
Kind
B2
Abstract

Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.

Claims (1)

1. A method of diagnosing or monitoring choroidal neovascularization or wet macular degeneration, comprising administering a labeled CCR3-specific binding molecule to a patient and detecting the presence or absence of the labeled CCR3-specific binding molecule in the choroid of the patient, wherein the presence of the labeled CCR3-specific binding molecule being indicative of choroidal neovascularization or wet macular degeneration in said patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2008
From: AMBATI, JAYAKRISHNA
To: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
Reel/Frame 022032/0512 →
Continuity (2)
Provisional Application 60998348 · Oct 9, 2007
Related Publication 20090123375A1 · May 14, 2009